Document is current

Article History

Received: 15 June 2023

Revised: 28 October 2024

Accepted: 5 November 2024

First Online: 29 November 2024

Competing interests

: Authors are interested in the development of therapeutics for the TMBIM family, one of which is described in this article. Although MicroQuin has a commercial interest in MQT, MicroQuin’s lead therapeutics are small molecules and not peptides. MicroQuin’s small molecules act akin to MQT, but the data presented in this article is that of the peptide drug MQT. Several patents have been filed and are pending in relation to the activities of these products and the data presented in this article.

: All methods were performed in accordance with relevant guidelines, regulations, and best practices. For in vivo studies financed by CDMRP approval was sought from the USAMRDC Animal Care and Use Review Office (ACURO). Labcorp Early Development Laboratories Limited (formerly Covance) – Huntingdon (UK) F16-00136 (A5616-01) was used for in vitro anti-viral studies. LabCorp (formerly Covance) Ann Arbor, Michigan (USA) D16-00871 (A4671-01) and WuXi AppTec (Shanghai, China) Co., Ltd. F16-00281 (A5969-01) were used for in vivo studies. Human data regarding TMBIM6 expression in patient biopsies was obtained from ProteinAtlas and NCI GEO databases. Informed consent was obtained from all patients for tissue samples to be used and analyzed. No images or identifiable information is provided or alluded to in this article about any participants.